Anti-TNF-α therapy in seven patients with Behçet's uveitis: Advantages and controversial aspects

Annals of the New York Academy of Sciences

Volumn 1110, Issue , 2007, Pages 474-484

  Tognon, S ^a   Graziani, G ^a   Marcolongo, Renzo ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Beh et's disease; Infliximab; TNF ; Uveitis

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FOLIC ACID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ASTHENIA; BEHCET DISEASE; BEHCET UVEITIS; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUSHING; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; RECURRENT DISEASE; SIDE EFFECT; THORAX PAIN; VISUAL ACUITY;

EID: 35748951621     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1423.050     Document Type: Conference Paper

References (29)

1. EVEREKLIOGLU, C. 2005. Current concepts in the etiology and treatment of Behçet disease. Surv. Ophthalmol. 50: 297-350.
2. EMMI, L., M. FALCHI & S. PURICELLI. 1997. Pathogenesis and therapy of Behçet's disease. Ann. Ital. Med. 12: 20-27.
3. DIRESKENELI, H. 2001. Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann. Rheum. Dis. 60: 996-1002.
4. ARAYSSI, T. & A. HAMDAN. 2004. New insight into the pathogenesis and therapy of Behçet's disease. Curr. Opin. Pharmacol. 4: 183-188.
5. REPORT OF THE INTERNATIONAL TEAM FOR THE REVISION OF THE INTERNATIONAL CRITERIA FOR BEHÇET'S DISEASE (ITR-ICBD). 2006. Evaluation of the International Criteria for Behçet's Disease (ICBD) [abstract]. Clin. Exp. Rheumatol. 24(Suppl. 42): S13/B4.
6. ITR-ICBD. 2006. Revision of the International Criteria for Behçet's Disease [abstract]. Clin. Exp. Rheumatol. 24(Suppl. 42): S14/B10.
7. TUGAL-TUTKUN, I., S. ONAL, et al. 2004. Uveitis in Behçet disease: an analysis of 880 patients. Am. J. Ophthalmol. 138: 373-380.
8. YOSHIDA, A., H. KAWASHIMA, et al. 2004. Comparison of patients with Behçet's disease in the 1980s and 1990s. Ophthalmology 111: 810-815.
9. DESAI, S. & E. FURST. 2006. Problems encountered during anti-tumour necrosis factor therapy. Best Prac. Res. Clin. Rheumatol. 20: 757-790.
10. TUGAL-TUTKUN, I., A. MUDUN, et al. 2005. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine and corticosteroids in Behçet's disease. Arthritis Rheum. 52: 2478-2484.
11. SFIKAKIS, PP., P.H. KAKLAMANIS, et al. 2004. Infliximab for recurrent sight-threatening ocular inflammation in Adamantiades-Behçet's disease. Ann. Int. Med. 140: 404-406.
12. LINDSTEAD, E.W., G.S. BAARSMA, et al. 2005. Anti-TNF-α therapy for sight threatening uveitis. Br. J. Ophthalmol. 89: 533-536.
13. JOSEPH, A., D. RAJ, et al. 2003. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110: 1449-1453.
14. OHNO, S., S. NAKAMURA, et al. 2004. Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J. Rheumatol. 31: 1362-1368.
15. WECHSLER, B., R. SABLE-FOURTASSOU, et al. 2004. Infliximab in refractory uveitis due to Behçet's disease. Clin. Exp. Rheumatol. 22(4 Suppl. 34): s14-s16.
16. LOPEZ-GONZALEZ, R., C. HERNANDEZ-G ARCIA, et al. 2006. Efficacy and safety of treatment with infliximab in refractory posterior uveitis/ five years follow-up [abstract]. Arthrits Rheum. 54(Suppl): 1621/292.
17. LANTHIER, N.C., PARC C, et al. 2005. Infliximab in the treatment of posterior uveitis in Behçet's disease. Press. Med. 34: 916-918.
18. EL-ASRAR, A.M., E.B. ABBOUD, et al. 2005. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int. Ophthalmol. 26: 83-92.
19. WECHSLER, B., B. BODAGHI, et al. 2006. Long term follow-up of infliximab in refractory panuveitis due to Behçet's disease [abstract]. Clin. Exp. Rheumatol. 24(Suppl 42): S25/D4.
20. SUHLER, E.B., J.R. SMITH, et al. 2005. A prospective trial of infliximab therapy for refractory uveitis. Arch. Ophthalmol. 123: 903-912.
21. BODAGHI, B. & M. DE SMET FOR THE RESCUE TRIAL PARTICIPANTS. 2006. Infliximab for severe uveitis: forty-six weeks efficacy and safety results from the Remicade European Study for Chronic Uveitis (RESCUE) [abstract]. Clin. Exp. Rheumatol. 24(Suppl 42): S29/E15.
22. MONNET, D., L. MOACHON, et al. 2006. Severe uveitis in an HLA-B27 positive patient with ankylosing spondylitis. Nat. Clin. Pract. Rheumatol. 2: 393-397.
23. TABAN, M., W.J. DUPPS, et al. 2006. Etanercept (Enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul. Immunol. Inflamm. 14: 145-150.
24. VAN LAAR, J.A.M., J.H. KAPPEN, et al. 2006. Adalimumab: a new modality for sight-threatening uveitis in Behçet's disease [abstract]. Clin. Exp. Rheumatol. 24(Suppl. 42): S35/H4.
25. VINAGRE, F., S. GRACES, et al. 2006. Adalimumab in Behçet's disease: case report [abstract]. Clin. Exp. Rheumatol. 24(Suppl. 42): S36/H11.
26. ESTRACH, C., S. MPOFU & R.J. MOOTS. 2002. Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatology 41: 1213-1214.
27. GALOR, A., V.L. PEREZ, et al. 2006. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 113: 2317-2323.
28. SCOTT, D.L. & G.H. KINGSLEY. 2006. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Eng. J. Med. 355: 704-712.
29. MARCOLONGO, R. & AMP; L. BONADIMAN. 2004. Really expert patients can "empower" doctors. BMJ.com. 328(7442): rapid responses.